FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN -BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIAS PATIENTS AT FIRST RELAPSE

Trial Profile

FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN -BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIAS PATIENTS AT FIRST RELAPSE

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 Planned number of patients changed from 61 to 38.
    • 16 Mar 2017 Planned End Date changed from 1 Jul 2018 to 1 Dec 2020.
    • 16 Mar 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top